Advanced NSCLC: patients rank treatment side effects from bad to worst

  • Islam KM & al.
  • BMC Cancer
  • 27/08/2019

  • Craig Hicks
  • Univadis Clinical Summaries
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Patients with advanced-stage NSCLC rank shortness of breath, bleeding, and fatigue as the adverse effects of chemotherapy they would most like to avoid.

Why this matters

  • Coupling patient preferences and profiles of commonly used chemotherapy regimens could result in patient-centered treatment plans with better outcomes.

Study design

  • Researchers studied the treatment choices of patients with advanced-stage NSCLC (n=232; 55.6% men; 95.3% white) based on medical records and interviews.
  • Funding: Patient-Centered Outcomes Research Institute.

Key results

  • Before and after experiencing chemotherapy, patients selected the adverse effect they would most like to avoid:
    • Shortness of breath (before, 28.7%; after, 20.8%);
    • Unusual or increased bleeding (20.9%; 14.3%);
    • Decreased energy or excessive fatigue (11.9%; 25.6%);
    • Dizziness (10.8%; 10.7%);
    • A lot more expensive (8.4%; 9.5%);
    • Jaundice (8.4%; 7.7%);
    • More trips to clinic for treatment (7.2%; 7.1%);
    • Numbness or tingling (1.8%; 1.2%); and
    • Brittle nails (1.8%; 2.9%).

Limitations

  • Study data are not publicly available to protect patient confidentiality.
  • Checkpoint inhibitors were not an approved first-line treatment during the study.
  • Study results are limited to patients with advanced NSCLC.